Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
2.67M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
178K
-
Shares change
-
+40.1K
-
Total reported value, excl. options
-
$424K
-
Value change
-
+$88.6K
-
Number of buys
-
3
-
Number of sells
-
-3
-
Price
-
$2.37
Significant Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) as of Q2 2024
8 filings reported holding LIXT - LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share as of Q2 2024.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 178K shares
of 2.67M outstanding shares and own 6.69% of the company stock.
Largest 8 shareholders include HighTower Advisors, LLC (99.4K shares), FNY Investment Advisers, LLC (50.3K shares), Ethos Financial Group, LLC (24.8K shares), Tower Research Capital LLC (TRC) (3.22K shares), UBS Group AG (345 shares), BANK OF AMERICA CORP /DE/ (309 shares), WELLS FARGO & COMPANY/MN (0 shares), and MORGAN STANLEY (0 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.